05:37 PM EDT, 08/03/2026 (MT Newswires) -- GeneDx ( WGS ) reported Q2 adjusted earnings late Monday of $0.01 per diluted share, down from $0.55 a year earlier.

Analysts polled by FactSet expected loss of $0.19.

Revenue for the quarter ended June 30 was $114.4 million, up from $102.7 million a year earlier.

Analysts expected $111.0 million.

For Q3, the company expects revenue of $122 million to $124 million. Analysts expect $126.1 million.

The company expects 2026 revenue of $475 million to $490 million. Analysts expect $478.4 million.

Shares of GeneDx ( WGS ) rose 12% during after-hours activity.